Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Express Scripts
Merck
Moodys
Mallinckrodt

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,774,104

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,774,104 protect, and when does it expire?

Patent 6,774,104 protects MYCAMINE and is included in one NDA.

This patent has forty patent family members in twenty-eight countries.

Summary for Patent: 6,774,104
Title: Stabilized pharmaceutical composition in lyophilized form
Abstract:A stabilized pharmaceutical composition in lyophilized form comprising: a cyclic polypeptide compound represented by the general formula (I): ##STR1## wherein R.sup.1 is a hydrogen atom or an acyl group and R.sup.2 and R.sup.3 are, the same or different, a hydrogen atom or a hydroxyl group, or a salt thereof and the stabilizer.
Inventor(s): Sawai; Seiji (Hyogo, JP), Kasai; Akihiro (Nara, JP), Otomo; Kazumi (Osaka, JP)
Assignee: Fujisawa Pharmaceutical Co., Ltd. (Osaka, JP)
Application Number:09/786,125
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,774,104
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation; Use;

Drugs Protected by US Patent 6,774,104

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astellas MYCAMINE micafungin sodium INJECTABLE;INTRAVENOUS 021506-002 Mar 16, 2005 AP RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS   Start Trial
Astellas MYCAMINE micafungin sodium INJECTABLE;INTRAVENOUS 021506-002 Mar 16, 2005 AP RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES   Start Trial
Astellas MYCAMINE micafungin sodium INJECTABLE;INTRAVENOUS 021506-003 Jun 27, 2006 AP RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS   Start Trial
Astellas MYCAMINE micafungin sodium INJECTABLE;INTRAVENOUS 021506-003 Jun 27, 2006 AP RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,774,104

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan11/187713Jul 01, 1999
PCT Information
PCT FiledJune 29, 2000PCT Application Number:PCT/JP00/04381
PCT Publication Date:January 11, 2001PCT Publication Number: WO01/02002

International Family Members for US Patent 6,774,104

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 024634   Start Trial
Austria 280583   Start Trial
Australia 5572200   Start Trial
Australia 752265   Start Trial
Brazil 0006823   Start Trial
Canada 2341568   Start Trial
China 100352495   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Harvard Business School
Moodys
AstraZeneca
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.